Sumitomo Chemical India Ltd
Sumitomo Chemical India Ltd
CommoditiesKey Fundamentals
SmallcapPesticides & AgrochemicalsChemicalsInsights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sumitomo Chemical India Ltd insights
52 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
2- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 34.5%
Weaknesses
2- Stock is trading at 8.26 times its book value
- The company has delivered a poor sales growth of 3.81% over past five years.
Growth Rate
AI Analysis — Bull vs Bear
Sumitomo Chemical India Ltd is a nearly debt-free agrochemical company with a market cap of ₹28,239 Cr trading at a PE of 48.6x and PB of 8.31x. Sales have declined at -3% CAGR over the last 3 years while profit growth has been modest at 3% CAGR over the same period, though the company maintains a consistent ROE averaging 17-20% over the past decade.
- Company is almost debt-free, providing significant financial flexibility and resilience during downturns
- Consistent ROE of 17-20% over 3, 5, and 10-year periods indicates efficient capital allocation and strong return generation
- Long-term compounded profit growth of 24% over 10 years demonstrates a strong earnings track record
- Healthy dividend payout ratio of 34.5% signals shareholder-friendly capital return policy
- 10-year compounded sales growth of 16% shows the company has scaled meaningfully over the long term
- Stock price CAGR of 11% over 3 years despite weak recent sales, suggesting market confidence in earnings recovery
- TTM profit growth of 3% remains positive even as sales declined by 3%, indicating margin resilience and cost discipline
- PE ratio of 48.6x is elevated, demanding significant future growth to justify current valuation
- Stock is trading at 8.31x book value, which is expensive relative to most industrial/commodity peers
- Compounded sales growth of -3% over 3 years and -3% TTM shows revenue contraction in the medium term
- 5-year sales CAGR of only 3.81% is poor for a company trading at premium multiples
- 1-year stock price return of -4% indicates recent underperformance and negative market sentiment
- Dividend yield of just 0.23% provides minimal income cushion for investors at current prices
- Compounded profit growth has slowed sharply from 24% over 10 years to just 3% over the last 3 years, signaling earnings deceleration
- 5-year stock CAGR of only 7% is modest given the premium valuation, suggesting limited price appreciation relative to risk
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Q1FY27 net profit up 20% YoY Jul 27
Sumitomo Chemical India reported standalone net profit of ₹2,165.29 million (₹214.5 crore) in Q1FY27, a 20.4% YoY rise aided by margin expansion and an insurance claim.
- Parent Q1 EPS turns positive Aug 4
Parent Sumitomo Chemical reported Q1 EPS of $0.77, a sharp turnaround from $(0.10) loss in the year-ago quarter, though sales dipped 0.47% to $3.623 billion.
- ₹1.30 per share dividend declared Jul 27
Board approved a dividend of ₹1.30 per share at the 26th AGM on July 27, 2026, alongside board restructuring with new independent directors.
- Parent affirms FY26 guidance Aug 4
Sumitomo Chemical confirmed FY2026 sales guidance at $15.047 billion and GAAP EPS target of $1.35, maintaining previous financial expectations.
- Analyst meet scheduled Aug 19 Aug 10
Sumitomo Chemical India will host a group meeting with investors and analysts on August 19, 2026, at 3:00 PM IST in Mumbai, organized by Motilal Oswal.
- Director Ninad Gupte resigns Jul 27
Ninad D. Gupte's resignation as Non-Executive, Non-Independent Director was accepted, effective August 31, 2026, citing personal reasons.
TL;DR: Sumitomo Chemical India delivered a strong Q1FY27 with 20% profit growth and declared a healthy dividend, while the parent company's EPS turnaround and guidance reaffirmation signal stability. No material headwinds emerged in recent news. The trend is improving with operational momentum and margin expansion, though the insurance claim benefit is non-recurring and investors should watch for sustaining organic growth in coming quarters.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 724 | 903 | 540 | 664 | 832 | 971 | 622 | 665 | 1,048 | 914 | 552 | 671 | 1,054 |
| Expenses | 643 | 715 | 474 | 526 | 670 | 729 | 521 | 548 | 828 | 697 | 456 | 539 | 819 |
| Operating Profit | 81 | 188 | 66 | 139 | 162 | 242 | 101 | 117 | 220 | 217 | 96 | 133 | 235 |
| OPM % | 11% | 21% | 12% | 21% | 19% | 25% | 16% | 18% | 21% | 24% | 17% | 20% | 22% |
| Other Income | 18 | 25 | 27 | 27 | 26 | 31 | 31 | 31 | 39 | 39 | 22 | 32 | 74 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| Depreciation | 14 | 16 | 16 | 16 | 14 | 15 | 18 | 16 | 15 | 16 | 16 | 16 | 16 |
| PBT | 83 | 196 | 76 | 149 | 173 | 257 | 113 | 132 | 242 | 238 | 100 | 147 | 291 |
| Tax % | 26% | 27% | 27% | 26% | 26% | 26% | 25% | 25% | 26% | 25% | 25% | 25% | 26% |
| Net Profit | 62 | 144 | 55 | 109 | 128 | 191 | 84 | 98 | 180 | 178 | 75 | 111 | 217 |
| EPS in Rs | 1.24 | 2.88 | 1.1 | 2.19 | 2.57 | 3.82 | 1.69 | 1.97 | 3.6 | 3.56 | 1.5 | 2.22 | 4.34 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 671 | 724 | 799 | 1,911 | 2,223 | 2,423 | 2,643 | 3,060 | 3,511 | 2,833 | 3,090 | 3,186 | 3,192 |
| Expenses | 614 | 635 | 698 | 1,691 | 1,932 | 2,088 | 2,155 | 2,458 | 2,843 | 2,358 | 2,467 | 2,520 | 2,511 |
| Operating Profit | 57 | 89 | 101 | 219 | 291 | 335 | 488 | 603 | 668 | 474 | 623 | 666 | 680 |
| OPM % | 8% | 12% | 13% | 11% | 13% | 14% | 18% | 20% | 19% | 17% | 20% | 21% | 21% |
| Other Income | 8 | 26 | 10 | 31 | 0 | -20 | 19 | 36 | 45 | 96 | 119 | 131 | 166 |
| Interest | 1 | 1 | 1 | 5 | 5 | 7 | 7 | 8 | 6 | 5 | 6 | 7 | 7 |
| Depreciation | 6 | 7 | 7 | 24 | 28 | 41 | 47 | 45 | 52 | 61 | 63 | 63 | 64 |
| PBT | 58 | 107 | 103 | 221 | 258 | 267 | 453 | 586 | 655 | 503 | 674 | 727 | 776 |
| Tax % | 40% | 40% | 40% | 34% | 35% | 23% | 24% | 26% | 23% | 27% | 26% | 25% | — |
| Net Profit | 35 | 65 | 62 | 145 | 167 | 206 | 345 | 434 | 503 | 370 | 502 | 543 | 580 |
| EPS in Rs | — | — | — | — | — | 4.12 | 6.92 | 8.69 | 10.09 | 7.41 | 10.06 | 10.88 | 11.62 |
| Div. Payout % | 0% | 0% | 0% | 0% | 38% | 18% | 12% | 12% | 12% | 80% | 12% | 12% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 233 | 233 | 275 | 275 | 275 | 499 | 499 | 499 | 499 | 499 | 499 | 499 |
| Reserves | -2 | 63 | 360 | 665 | 761 | 710 | 1,029 | 1,425 | 1,881 | 1,941 | 2,397 | 2,885 |
| Borrowings | 0 | 0 | 0 | 10 | 20 | 36 | 33 | 38 | 34 | 25 | 45 | 53 |
| Other Liabilities | 234 | 280 | 288 | 695 | 791 | 848 | 1,097 | 1,047 | 955 | 822 | 988 | 997 |
| Total Liabilities | 466 | 576 | 922 | 1,644 | 1,846 | 2,093 | 2,658 | 3,009 | 3,368 | 3,287 | 3,930 | 4,434 |
| Fixed Assets | 51 | 52 | 53 | 267 | 279 | 319 | 309 | 390 | 430 | 489 | 482 | 499 |
| CWIP | 0 | 1 | 7 | 9 | 8 | 10 | 14 | 35 | 71 | 23 | 28 | 20 |
| Investments | 0 | 0 | 277 | 2 | 1 | 87 | 291 | 357 | 239 | 425 | 601 | 1,226 |
| Other Assets | 415 | 523 | 585 | 1,367 | 1,558 | 1,676 | 2,043 | 2,227 | 2,628 | 2,351 | 2,819 | 2,690 |
| Total Assets | 466 | 576 | 922 | 1,644 | 1,846 | 2,093 | 2,658 | 3,009 | 3,368 | 3,287 | 3,930 | 4,434 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 4 | 52 | -21 | 49 | 75 | 222 | 424 | 223 | 389 | 756 | 458 | 443 |
| Investing | -8 | -5 | -289 | -40 | -35 | -118 | -282 | -281 | -327 | -426 | -405 | -329 |
| Financing | 0 | 0 | 276 | 7 | -65 | -61 | -47 | -63 | -73 | -331 | -65 | -81 |
| Net Cash Flow | -4 | 47 | -34 | 16 | -26 | 43 | 95 | -120 | -10 | -1 | -11 | 33 |
| Free Cash Flow | -6 | 44 | -310 | 6 | 36 | 184 | 382 | 111 | 270 | 695 | 431 | 404 |
| CFO/OP | 44 | 102 | 14 | 60 | 56 | 90 | 109 | 61 | 83 | 187 | 100 | 91 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 83 | 92 | 101 | 105 | 110 | 128 | 117 | 101 | 98 | 91 | 90 | 81 |
| Inventory Days | 135 | 169 | 191 | 202 | 193 | 133 | 185 | 198 | 157 | 135 | 154 | 166 |
| Days Payable | 109 | 132 | 115 | 176 | 136 | 112 | 145 | 110 | 87 | 96 | 107 | 86 |
| Cash Conversion Cycle | 109 | 130 | 177 | 131 | 167 | 150 | 157 | 189 | 168 | 131 | 136 | 161 |
| Working Capital Days | 69 | 79 | 113 | 113 | 116 | 109 | 95 | 127 | 136 | 173 | 183 | 155 |
| ROCE % | 27% | 41% | 22% | 29% | 27% | 26% | 33% | 34% | 30% | 21% | 25% | 23% |
Documents
Frequently Asked Questions about Sumitomo Chemical India Ltd
What does Sumitomo Chemical India Ltd do?
Where is Sumitomo Chemical India Ltd (SUMICHEM) listed?
Which sector does Sumitomo Chemical India Ltd belong to?
What is the market capitalisation of Sumitomo Chemical India Ltd?
What is the PE ratio of Sumitomo Chemical India Ltd?
What is the 52-week high and low of Sumitomo Chemical India Ltd?
Does Sumitomo Chemical India Ltd pay dividends?
What is the Return on Equity (ROE) of Sumitomo Chemical India Ltd?
How can I research Sumitomo Chemical India Ltd on Tapetide?
Company Information
Sumitomo Chemical India Ltd. (SCIL) is one of the leading players in the industry which has a balanced portfolio of technical as well as formulation products along with backward integration for some products. The Company is known for domestic marketing of proprietary products of its Japanese parent -Sumitomo Chemical Company Limited in agrochemicals, animal nutrition, and environmental health business segments. With the integration of Excel Crop Care Limited, the Company now has a strong portfolio of generics in addition to specialty products and a strong combined marketing network. With this integration, the Company has moved up several notches in the pecking order of the Indian crop protection industry. SCIL has also marked its presence in Africa and several other geographies of the world.[1] [2]